A Phase 2, Single-Arm Open-Label Study of Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

In this study we want to find out more about the drug Abemaciclib in people with metastatic or unresectable soft tissue sarcoma or bone sarcoma. We want to find out whether Abemaciclib has anti-tumor effects that could potentially shrink the tumor. The FDA has approved Abemaciclib for treatment in breast cancer, but Abemaciclib is not approved by the FDA for the treatment of sarcoma. We do not yet know if it will help treat this cancer